RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Objective: To compare the safety and efficacy of radioembolization with that of sorafenib for the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).
Materials and Methods: MEDLINE, EMBASE, and Cochrane databases were searched for studies reporting outcomes in patients with HCC and PVTT treated with radioembolization or sorafenib. Meta-analyses of cumulative overall survival (OS) and Kaplan-Meier survival rates according to the time to progression (TTP) and incidence of adverse events (AEs) were performed. Subgroup analyses were conducted on 1-year OS data.
Results: Seventeen studies were identified (four involving radioembolization, 10 involving sorafenib, and three comparing both). Pooled OS rates were higher in the radioembolization group, notably at 6 months {76% (95% confidence interval [CI], 64–85%) vs. 54% (95% CI, 45–62%)} and 1 year (47% [95% CI, 38–57%] vs. 24% [95% CI, 18–30%]); TTP was also longer with radioembolization. In patients undergoing radioembolization, the proportion of patients with Eastern Cooperative Oncology Group status 0 (p < 0.0001), Child-Pugh A (p < 0.0001), extrahepatic metastasis (p = 0.0012), and a history of cancer treatment (p = 0.0048) was identified as a significant source of heterogeneity for the 1-year OS. Radioembolization was associated with a lower incidence of grade 3/4 AEs than sorafenib (9% [95% CI, 3–27%] vs. 28% [95% CI, 17–43%]).
Conclusion: Compared with sorafenib, radioembolization is a safer and more effective treatment for HCC with PVTT and is associated with prolonged survival, delayed tumor progression, and fewer grade 3/4 AEs.

참고문헌 (Reference)

1 Mazzaferro V, "Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study" 57 : 1826-1837, 2013

2 Edward Wolfgang Lee, "Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review" 대한영상의학회 17 (17): 472-488, 2016

3 Tsai AL, "Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis" 21 : 1377-1384, 2010

4 Han K, "Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review" 22 : 407-416, 2016

5 Kuo YH, "The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis" 36 : 307-314, 2018

6 Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration" 151 : W65-W94, 2009

7 Sterne JA, "Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis" 323 : 101-105, 2001

8 이준영, "Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers–Part II. Statistical Methods of Meta-Analysis" 대한영상의학회 16 (16): 1188-1196, 2015

9 Ali R, "Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status versus vascular invasion/metastases" 41 : 260-269, 2018

10 Zhang Y, "Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis" 20 : 1417-1424, 2015